Evaluation of the Moderna, Pfizer/Biotech, Astrazeneca/Oxford and Sputnik V Vaccines for Covid-19

  • De Soto J
N/ACitations
Citations of this article
55Readers
Mendeley users who have this article in their library.

Abstract

The SARs-CoV-2 (COVID-19) virus, which was first identified in December 2019, in Wuhan China is a respiratory virus that induces respiratory distress and a systemic inflammatory reaction in the vasculature mediated by a cytokine storm. Currently, 72 million people have been infected with 1.6 million deaths giving a mortality rate of 2.2% despite the best post-infective medical intervention available. Due to the rapid spread of the COVID virus and the worldwide pandemic that has developed, the rush for the development of a vaccine has become a priority amongst health care officials world-wide. In this review, we discuss what is currently known about the mechanism of action, efficacy, and toxicity of three of the most promising vaccines mRNA-1273 (Moderna), BNT162b2 (Pfizer/BioNtech), ChAdOx1 nCoV-19 (Astrazenac/Oxford), and rAd26)/rAd5 (Sputnik V) against COVID-19.

Cite

CITATION STYLE

APA

De Soto, J. A. (2021). Evaluation of the Moderna, Pfizer/Biotech, Astrazeneca/Oxford and Sputnik V Vaccines for Covid-19. Advance Research Journal of Medical Clinical and Science, 07(01). https://doi.org/10.15520/arjmcs.v7i01.246

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free